论文部分内容阅读
目的探讨醋酸地塞米松固体脂质纳米粒在小鼠体内的靶向性。方法用HPLC测定生物样品中醋酸地塞米松的含量,比较醋酸地塞米松纳米粒和原药给药后在不同时间各脏器的药物含量、各脏器中药物的量占给药量的百分数及药动学参数,以评价醋酸地塞米松固体脂质纳米粒的靶向性。结果在肺部,醋酸地塞米松纳米粒给药组的地塞米松含量、地塞米松量占给药量的百分数远高于原药给药组,两者的AUC值相差约16倍。结论醋酸地塞米松固体脂质纳米粒在小鼠体内具有肺靶向性。
Objective To investigate the targeting of dexamethasone acetate solid lipid nanoparticles in mice. Methods The contents of dexamethasone acetate in biological samples were determined by HPLC. The contents of drugs in different organs were compared between the dexamethasone acetate nanoparticles and the original drug. The percentage of drugs in each organ accounted for the dosage And pharmacokinetic parameters to evaluate the targeting of dexamethasone acetate solid lipid nanoparticles. Results In the lungs, the dexamethasone content and the percentage of dexamethasone in the administration group of dexamethasone acetate nanoparticles were much higher than that of the original drug administration group. The AUC values of the two groups differed by about 16 times. Conclusion Dexamethasone acetate solid lipid nanoparticles have lung targeting in mice.